estimated cost and effectiveness for four treatment strategies: 1) Standard dual therapy pegylated interferon alfa and ribavirin (PR); 2) BOCϩPR triple therapy; 3) TELϩPR triple therapy; and 4) no treatment. RESULTS: In our model, patients received 1) PR for 48 weeks; 2) TEL for 12 weeks with PR for 34-36 weeks; or 3) BOC for 29 weeks with PR for 34-36 weeks. Estimated treatment cost associated with PR alone, BOCϩPR, and TELϩPR are about $8,300, $31,000 and $45,000 per average patient, respectively. Total system-wide costs to adopt BOCϩPR or TELϩPR would be $673 million and $971 million, respectively. Assuming continuation of the current 21% VHA treatment rates and optimal SVR results, the long term reduction in liver related death from treatment PR, BocϩPR, and TelϩPR are 7.9%, 13.1%, and 14.5%, respectively. CONCLUSIONS: Our model indicates upfront investments with BOCϩPR, and TELϩPR are high, with the benefits of extending quality of life and lower costs due to liver-related morbidity. Though model projected potential cost under these assumptions, a clinical trial of comparative effectiveness would be needed to evaluate both costs and benefits of DAAs in veterans. 
PIN27 COST ANALYSIS OF THE CONSUMED ORAL ANTIBIOTICS IN A TERTIARY CARE HOSPITAL IN GALLE, SRI LANKA
University of Ruhuna, Faculty of Medicine, Galle, Sri Lanka, 2 
University of Ruhuna, Galle, Sri Lanka

OBJECTIVES:
Research data on antibiotic usage pattern and cost comparison are scant in our country. Therefore we planned to identify oral antibiotic (OA) consumption and cost comparison for 2010 in tertiary care hospital in Sri Lanka. METHODS: Aggregate data for 2010 was collected from records of pharmacy and unit price was obtained from medical supplies division. Initial and final stocks of the OA, quantity received, quantities issued, quantity consumed and hospital data from VEN analysis were obtained. We identified the top ten for total cost (TTTC) and top ten for consumption (TTCS) OA. RESULTS: Ninethy-three percent of total cost for TTTC was utilized for the top seven highly consumed OA with low unit price. Seven percent of TTTC had been utilized for the drugs which were not in TTCS. In contrast three drugs in TTCS had not been included in TTTC but in the list of top 20. Low quota ( 2.5%) of the TTTC had been utilized for non essential drug in VEN which was not even in TTCS of OA. CONCLUSIONS: Ninety-three percent of the cost has been effectively utilized highly consumed low cost OA in this hospital for 2010. Seven percent of money in TTTC was spent for expensive OA. We suggest the authority to reconsider the change the drug ordering pattern with minimum cost and to suitable alternative low cost generics instead of expensive product.
PIN28 CONSUMPTION PATTERN AND THE COST ANALYSIS OF PARENTERAL ANTIBIOTICS IN A
Hettihewa LM, Subasinghe S, Nilakshi K, Cooray P University of Ruhuna Faculty of Medicine, Galle, Sri Lanka OBJECTIVES: We planned to identify the 2010 parenteral antibiotic (PA) consumption pattern and its cost effectiveness in government teaching hospital using aggregate data. METHODS: Aggregate data for 2010 was collected from pharmacy records and unit prize was obtained from medical supplies division. Initial and final stocks of the OA, quantity received, quantities issued and consumed per year were obtained. Data for VEN analysis was collected. Data was analyzed to identify the top ten for total cost (TTTC) and top ten for consumption (TTCS) PA according to the total cost and the consumption separately. RESULTS: Ninety-three perecent of TTTC was utilized for the top 7 highly consumed OA with low unit prize. Seven percent of expenditure of TTTC was utilized for drugs which were not included in TTCS. In contrast 3% of drugs (3 OA) in TTCS had not been included in TTTC. This indicates that these three OAs are cost effectively used. 2.5% of the TTTC had been used for a non essential drug in VEN which was not included even in TTCS of OA. CONCLUSIONS: We conclude that 93% of the cost has been effectively utilized highly consumed low cost OA in this hospital for 2010. Seven percent of the TTTC had been spent for expensive oral antibiotics. We suggest the authority to reconsider the change the drug orders to maximize the cost effectiveness and prioritize alternative low cost generics instead of expensive product orders. 
PIN29 LINEZOLID VERSUS VANCOMYCIN FOR SKIN AND SOFT TISSUE INFECTIONS BY METHICILIN-RESISTANT STAPHYLOCOCCUS AUREUS: A COST COMPARISON ANALYSIS UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
OBJECTIVES:
One third of skin and soft tissue infections (SSTI) are caused by methicilin-resistant staphylococcus aureus (MRSA). This study aims to compare SSTI-MRSA treatment costs with linezolid versus branded and generic vancomycin under the Brazilian private payer perspective. METHODS: A cost comparison study was performed to compare linezolid versus generic and branded vancomycin. As supported by clinical studies, overall treatment duration of 15 days with linezolid and 14 days with vancomycin was considered, using PO linezolid after a minimum 4-days cycle of IV infusion while vancomycin (1g bid) was entirely IV. A decisiontree model simulated SSTI-MRSA treatment assuming linezolid (600mg bid) IV can be switched to PO after 4-days and patients can be discharged if PO is implemented at physician discretion. Length of stay (LOS) and IV linezolid duration were ranged in one-way sensitivity analysis. Only direct medical costs were included in the analysis (hospital charges, medical visits, medical supplies and drug acquisition costs) and unit costs were obtained from Brazilian official price lists (2010 USD values) . RESULTS: The linezolid scheme with 4-days IV (LOSϭ4 days) and 11-days PO resulted in overall costs per patient of 4089.58 USD, while branded and generic vancomycin exhibited 6657.33 USD and 6970,23 USD, respectively. The incremental cost of vancomycin-treated patients was driven by hospital daily charges, responsible for over 55% of the overall vancomycin costs. One-way sensitivity analysis revealed cost-savings for linezolid up to LOS Ն12 days, with overall costs per patient ranging from 4089.58 to 7428.84 USD if IV therapy was maintained throughout the inpatient period (LOSϭ15 days). CONCLUSIONS: Linezolid exhibited a costsaving profile over branded or generic vancomycin for the treatment of SSTI-MRSA under the Brazilian public payer perspective. This economic benefit was a direct result of potential early discharge of patients receiving PO linezolid. 
PIN30 COST ANALYSIS OF VORICONAZOLE VERSUS ITRACONAZOLE FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTION (IFI) IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) IN CANADA, FRANCE, GERMANY, AND THE UNITED STATES
OBJECTIVES:
Voriconazole (VOR) demonstrated better tolerability with a longer treatment duration and less concomitant systemic antifungal drugs (con AF) compared to itraconazole (ITR). This study assessed key cost components associated with prophylaxis treatment of IFI after allogeneic HSCT across 4 countries (Canada, France, Germany, and US). METHODS: A prospective open-label multicenter clinical trial (IMPROVIT) for primary IFI prophylaxis after HSCT included patientsϾϭ12 years who were randomized to oral VOR or oral ITR from HSCT day for at least 100 and up to 180 days. Trial data on the key medical resource utilization (including hospital days and con AF use) for the first 100 days were analyzed and valued in 2010 costs. RESULTS: A total of 224 patients were in VOR and 241 in ITR group, with similar demographics (average age 43-year, 59% male, 92% Caucasian). VOR patients (vs. ITR) had longer study drug exposure (median: 96 vs. 68 days, pϽ0.0001; mean: 68 vs. 60 days, pϭ0.0162) and were 2 times less likely (Pϭ0.0032) to use con AF. The average per-patient hospital cost for voriconazole (vs. itraconazole) was Can$27, 674 (vs. Can$29, 669), €13, 277 (vs. €13, 632), €15, 185 (vs. €15, 762), and $31, 916 (vs. $33, 521) in Canada, France, Germany, and the U.S., respectively. The average per-patient cost of con AF for voriconazole (vs. itraconazole) was Can$1028 (vs. Can$2290 pϭ0.0061), €2208 (vs. €4678, pϭ0.0095), €2422 (vs. €5033, pϭ0.0177), and $1,720 (vs. $3612, pϭ0.0146) in the study countries respectively. Total costs varied by country and were similar between treatment groups. The mean difference of 8 days in prophylaxis days between VOR and ITR was associated with 3.54%-4.55% reduction (depending on the country) in inpatient cost (all pϽ.0001) and 9.13%-11.82% reduction in con AF cost (all pϽ.01). CONCLUSIONS: Better tolerability of IFI prophylaxis after HSCT was associated with cost offsets due to reduced hospitalization and concomitant antifungal use.
PIN31 QUANTIFYING THE FINANCIAL AND DISEASE BURDEN ASSOCIATED WITH MOTHER TO CHILD TRANSMISSION OF HIV IN UGANDA
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